Project VerioVue Enhancements

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

116 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-07

Study Completion Date

2023-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this performance evaluation is to compare the blood glucose results obtained using the VerioVue Blood Glucose Monitoring System (BGMS) with those obtained from a validated comparator method (iSTAT 1 Analyser) using arterial blood. The main question the study aims to answer is:

How accurate is the VerioVue BGMS when compared to a product that has already been confirmed as accurate (iSTAT 1 Analyser) when hospital staff test arterial blood on these two types of instrument? Participants will have a small amount of blood taken from an existing arterial line.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

One Touch® Verio®IQ European Clinical Outcomes Study

NCT01631643

Diabetes

WITHDRAWN PHASE4

One Touch VerioIQ US Clinical Outcomes Study

NCT01627899

Diabetes

TERMINATED NA

Project Frazier 3 Regulatory Clinical Evaluation

NCT03515421

Diabetes Mellitus Healthy Volunteers

COMPLETED NA

Controlled Acute Hypoxia Study - Abbreviated Sensor Line

NCT02216344

Healthy Hypoxia

COMPLETED

OneTouch Verio Flex System Accuracy Evaluation

NCT03138174

Diabetes Mellitus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Up to two UK NHS hospital sites will be used to collect a minimum of 100 evaluable samples from participants fitted with an arterial line that meet the acceptance criteria. Consent will be obtained from the participants prior to taking part in the study. If the participant meets the enrolment criteria then demographics and medical history information will be collected. A small volume of blood (max 150µl) will be collected from an existing arterial line. The blood will then be applied to six investigational OneTouch VerioVue meters (with expanded haematocrit range 20-65%) fitted with OneTouch Verio test strips and the blood glucose meter readings recorded. Three different lots of test strips will be used in rotation across the study. Within 5 minutes of the last meter test, trained staff will use blood from the same sample and perform a test on the iSTAT Analyser to obtain the blood glucose, haematocrit and oxygen levels of the sample. No treatment decisions will be made based on the blood glucose results obtained for this study. The study documentation will be reviewed by LifeScan monitors for completeness and accuracy and the results entered into a validated database. The data will be extracted and statistically analysed to determine the accuracy of the arterial blood glucose results obtained using the OneTouch VerioVue BGMS when compared to the arterial blood glucose results obtained on the iSTAT 1 Analyser.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

In-patients cardiothoracic intensive care

In-patients in the cardiothoracic intensive care department that were at least 16 years old and were fitted with an arterial line. There was no requirement to have diabetes but the study aimed to recruit a minimum of 20% subjects with diabetes.

VerioVue Enhancements BGMS

Intervention Type DEVICE

Blood glucose monitoring system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VerioVue Enhancements BGMS

Blood glucose monitoring system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age - The potential Subject is at least 16 years old. Language - Subject reads and understands English. Informed Consent - The potential subject must read the Participant Information Sheet and sign the Informed Consent Form.

Subject agrees to provide relevant demographic, medical history, and prescription medication information.

The subject agrees to allow study staff access to medical records where necessary.

The Subject agrees to all aspects of the study process, including arterial blood draws performed by an HCP.